2018

150 руб.

Проблема приверженности к терапии в кардиологии

Кретов Е. И., Таркова А. Р., Анисимова В. Д., Козырь К. В., Гражданкин И. О., Байструков В. И., Зубарев Д. Д., Ибрагимов Р. У., Крестьянинов О. В., Хелимский Д. А., Найденов Р. А., Нарышкин И. А., Обединский А. А., Прохорихин А. А.
ФГБУ «Национальный медицинский исследовательский центр им. акад. Е. Н. Мешалкина» Минздрава России, Новосибирск, Россия

Ключевые слова: приверженность к терапии, кардиология, медикаментозное лечение

DOI: 10.18087/cardio.2018.9.10174

В обзорной статье приведены результаты исследований по оценке приверженности к медикаментозной терапии пациентов после выписки из стационара: проанализированы причины отсутствия приверженности, оценено влияние приверженности на ближайшие и отдаленные результаты хирургического и медикаментозного лечения, структурированы способы повышения приверженности к терапии, а также экономические аспекты.
  1. Santo K., Kirkendall S., Laba T. L. et al. Interventions to improve medication adherence in coronary disease patients: A systematic review and meta-analysis of randomised controlled trials. Eur J Prev Cardiol 2016;23 (10):1065–1076. DOI: 10.1177/2047487316638501.
  2. Sabate E., World H. O. WHO Adherence to Long Term Therapies Project, Global Adherence IN. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization 2003.
  3. Baroletti S and Dell’Orfano H. Medication adherence in cardiovascular disease. Circulation 2010;121:1455–1458. DOI: 10.1161/CIRCULATIONAHA.109.904003.
  4. Rodriguez F. C. C., Steg P. G., Kubhani D. J. et al. Predictors of longterm adherence to evidence-based cardiovascular disease medications in outpatient with stable atherotrombotic disease: findings from the REACH Registry. Clin Cardiol 2013;16:721–727. DOI: 10.1002/clc.22217.
  5. Yusuf S., Islam S., Chow C. K. et al. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet 2011;378:1231–1243. DOI: 10.1016/S0140–6736(11)61215–4.
  6. Hauptman P. J. Medication adherence in heart failure. Heart Fail Rev 2008;13:99–106. DOI: 10.1007/s10741‑007‑9020‑7.
  7. Leventhan M. J., Riegel B., Carlson B., De Geest S. Negotiating compliance in heart failure: remaining issues and questions. Eur J Cardiovasc Nurs 2005;4:298–307. DOI: 10.1016/j.ejcnurse.2005.04.001.
  8. Claxton A. J., Cramer J., Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001;23 (8):1296–310. DOI: 10.1016/S0149–2918(01)80109–0.
  9. Ho P. M., Rumsfeld J. S., Masoudi F. A. et al. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Arch Intern Med 2006;166 (17):1836–1841. DOI: 10.1001/archinte.166.17.1836.
  10. Chowdhury R., Khan H., Heydon E. et al. Adherence to cardiovascular therapy: a meta-analysis of prevalence and clinical consequences. Eur Heart J 2013;34 (38):2940–2948. DOI: 10.1093/eurheartj/eht295.
  11. Corrao G., Rea F., Ghirardi A. et al. Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice. Hypertension 2015;66 (4):742–749. DOI: 10.1161/HYPERTENSIONAHA.115.05463.
  12. Petrilla A. A., Benner J. S., Battleman D. S. et al. Evidence-based interventions to improve patient compliance with antihypertensive and lipid-lowering medication. Int J Clin Pract 2005;59 (12):1441–1451. DOI: 10.1111/j.1368–5031.2005.00704.x.
  13. Sever P. S., Dahlöf B., Poulter N. R. et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicenter randomized controlled trial. Lancet 2003;361:1149–1158. DOI: 10.1016/S0140–6736(03)12948–0.
  14. Armstrong E. J., Chen D. C., Westin G. G. et al. Adherence to guideline-recommended therapy is associated with decreased major adverse cardiovascular events and major adverse limb events among patients with peripheral arterial disease. J Am Heart Assoc 2014;3(2):e000697. DOI: 10.1161/JAHA.113.000697.
  15. Ho P. M., Spertus J. A., Masoudi F. A. et al. Impact of medication therapy discontinuation on mortality after myocardial infarction. Arch Intern Med 2006;166:1842–1847. DOI: 10.1001/archinte.166.17.1842.
  16. Bell C. M. B. S., Gunraj N., Huo C. et al. Association of ICU or hospital admission with unintentional discontinuation of medications for chronic diseases. JAMA 2011;306:840–847. DOI: 10.1001/jama.2011.1206.
  17. Jackevicius C. A., Li P., Tu J. V. Prevalence, predictors, and outcomes of primary non-adherence after acute myocardial infarction. Circulation 2008;117:1028–1036. DOI: 10.1161/circulationaha.107.706820.
  18. Rasmussen J. N., Chong A., Alter D. A. Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction. JAMA 2007;297:177–186. DOI: 10.1001/jama.297.2.177.
  19. Allonen J., Nieminen M. S., Lokki M. et al. Mortality rate increases steeply with non-adherence to statin therapy in patients with acute coronary syndrome. Clin Cardiol 2012;35: E22–7. DOI: 10.1002/clc.22056.
  20. Kurlansky P., Herbert M., Prince S., Mack M. Coronary Artery Bypass Graft Versus Percutaneous Coronary Intervention: Meds Matter: Impact of Adherence to Medical Therapy on Comparative Outcomes. Circulation 2016;134 (17):1238–1246. DOI: 10.1161/CIRCULATIONAHA.115.021183.
  21. Mehran R., Baber U., Steg P. G. et al. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet 2013;382:1714–1722. DOI: 10.1016/S0140–6736(13)61720–1.
  22. Iakovou I., Schmidt T., Bonizzoni E. et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drugeluting stents. JAMA 2005;293:2126–2130. DOI: 10.1001/jama.293.17.2126.
  23. Collet J. P., Montalescot G., Steg P. G. et al. Clinical outcomes according to permanent discontinuation of clopidogrel or placebo in the CHARISMA trial. Arch Cardiovasc Dis 2009;102:485–496. DOI: 10.1016/j.acvd.2009.03.012.
  24. Granger B. B. S. K., Ekman I., Granger C. B. et al. Adherence to candesartan and placebo and outcomes in chronic heart failure in the CHARM programme: doubleblind, randomised, controlled clinical trial. Lancet 2005;366:2005–2011. DOI: 10.1016/S0140–6736(05)67760–4.
  25. Steg P. G., Harrington R. A., Emanuelsson H. et al. Stent thrombosis with ticagrelor versus clopidogrel in patients with acute coronary syndromes: an analysis from the prospective, randomized PLATO trial. Circulation 2013;128:1055–1065. DOI: 10.1161/CIRCULATIONAHA.113.002589.
  26. Serebruany V., Rao S. V., Silva M. A. et al. Correlation of inhibition of platelet aggregation after clopidogrel with post discharge bleeding events: assessment by different bleeding classifications. Eur Heart J 2009;2:227–235. DOI: 10.1093/eurheartj/ehp434.
  27. Wouters H., Van Dijk L., Geers H. C. J. et al. Understanding Statin Non-Adherence: Knowing Which Perceptions and Experiences Matter to Different Patients. PLoS ONE 2016;11 (1): e0146272. DOI: 10.1371/journal.pone.0146272.
  28. Kassab Y., Hassan Y., Abd Aziz N. et al. Patients’ adherence to secondary prevention pharmacotherapy after acute coronary syndromes. Int J Clin Pharm 2013;35:275–280. DOI: 10.1007/s11096‑012‑9735‑y.
  29. Melloni C., Alexander K. P., Ou F. S. et al. Predictors of early discontinuation of evidence-based medicine after acute coronary syndrome. Am J Cardiol 2009;104:175–181. DOI: 10.1016/j.amjcard.2009.03.013.
  30. Thom S., Poulter N., Field J. et al. Effects of a fixed-dose combination strategy on adherence and risk factors in patients with or at high risk of CVD: the UMPIRE randomized clinical trial. JAMA 2013;310:918–929. DOI: 10.1001/jama.2013.277064.
  31. Ruxin J., Paluzzi J. E., Wilson P. A. et al. Emerging consensus in HIV /AIDS, malaria, tuberculosis, and access to essential medicines. Lancet 2005;365:618–621. DOI: 10.1016/S0140–6736(05)17914–8.
  32. Jackevicius C. A., Mamdani M., Tu J. V. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA 2002;288:462–467. DOI: 10.1001/jama.288.4.462.
  33. Oates D. J., Paasche-Orlow M. K. Health literacy: communication strategies to improve patient comprehension of cardiovascular health. Circulation 2009;119:1049–1051. DOI: 10.1161/CIRCULATIONAHA.108.818468.
  34. Kumbhani D. J., Fonarow G. C., Cannon C. P. et al. Predictors of adherence to performance measures in patients with acute myocardial infarction. Am J Med 2013;126:74 e71–e79. DOI: 10.1016/j.amjmed.2012.02.025.
  35. Gukathasan N., Witzenbichler B., Weisz G. et al. Impact of gender of patterns of dual antiplatelet therapy cessation and nonadherence: one-year results from the patterns of non-adherence to anti-platelet regimens in stented patients (PARIS), an observational single-arm study. J Am Coll Cardiol 2013;61: E1531. DOI: 10.1016/s0735–1097(13)61531–4.
  36. Berry S. D., Quach L., Procter-Gray E. et al. Poor Adherence to Medications May Be Associated with Falls. J Gerontol A BiolSci Med Sci 2010; 65A (5):553–558. DOI: 10.1093/gerona/glq027.
  37. Glassman A. H., O’Connor C. M., Califf R. M. et al. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701–709. DOI:10.1001/jama.288.6.701
  38. Weidenbacher H. J., Beadles C. A., Maciejewski M. et al. Extent and reasons for nonadherence to antihypertensive, cholesterol, and diabetes medications: the association with depressive symptom burden in a sample of American veterans. Patient Preference and Adherence 2015;9:327–336. DOI: 10.2147/PPA.S74531.
  39. Kronish I. M., Edmondson D., Goldfinger J. Z. et al. Posttraumatic stress disorder and adherence to medications in survivors of strokes and transient ischemic attacks. Stroke 2012;43:2192–2197. DOI: 10.1161/STROKEAHA.112.655209.
  40. Williams L., O’Connor R. C., Grubb N., O’Carroll R. Type D personality predicts poor medication adherence in myocardial infarction patients. Psychol Health 2011;26:703–712. DOI: 10.1080/08870446.2010.488265.
  41. Britten N., Stevenson F. A., Barry C. A. et al. Misunderstandings in prescribing decisions in general practice: qualitative study. BMJ 2000;320:484–488. DOI: 10.1136/bmj.320.7233.484.
  42. Luders S., Schrader J., Schmieder R. E. et al. Improvement of hypertension management by structured physician education and feedback system: cluster randomized trial. Europ J Cardiovasc Prev Rehabil 2010; 17:271–279. DOI: 10.1097/HJR.0b013e328330be62.
  43. Hines R., Stone N. J. Patients and Physicians Beliefs and Practices Regarding Adherence to Cardiovascular Medication. JAMA Cardiol 2016;1 (4):470–473. DOI: 10.1001/jamacardio.2016.0634.
  44. Bourdes V., Ferrieres J., Amar J. et al. Prediction of persistence of combined evidence-based cardiovascular medications in patients with acute coronary syndrome after hospital discharge using neural networks. Med Biol Eng Comput 2011;49:947–955. DOI: 10.1007/s11517‑011‑0785‑4.
  45. Park L. G., Howie-Esquivel J., Chung M. L., Dracup K. A text messaging intervention to promote medication adherence for patients with coronary heart disease: a randomized controlled trial. Patient Educ Couns 2014;94 (2):261–268. DOI: 10.1016/j.pec.2013.10.027.
  46. Pomerantz J. M. Improving Medication Adherence: A New Marketing Opportunity for the Pharmaceutical Industry. Posted: 06/24/2004; 2004 Cliggott Publishing, Division of CMP Healthcare Media.
  47. Derose S. F., Green K., Marrett E. et al. Automated outreach to increase primary adherence to cholesterol-lowering medications. JAMA Intern Med 2013;173:38–43. DOI: 10.1001/2013.jamainternmed.717.
  48. Lee J. K., Grace K. A., Taylor A. J. Effect of a pharmacy care program on medication adherence and persistence, blood pressure, and lowdensity lipoprotein cholesterol: a randomized controlled trial. JAMA 2006;296:2563–2571. DOI: 10.1001/jama.296.21.joc60162.
  49. Friedman R. H., Kazis L. E., Jette A. et al. A telecommunications system for monitoring and counseling patients with hypertension. Impact on medication adherence and blood pressure control. Am J Hypert 1996;9:285–292. DOI: 10.1016/0895–7061(95)00353–3.
  50. Rinfret S., Rodes-Cabau J., Bagur R. et al. Telephone contact to improve adherence to dual antiplatelet therapy after drugeluting stent implantation. Heart 2013;99:562–569. DOI: 10.1136/heartjnl-2012–303004.
  51. Khonsari S., Subramanian P., Chinna K. et al. Effect of a reminder system using an automated short message service on medication adherence following acute coronary syndrome. Eur J Cardiovasc Nurs 2015;14 (2):170–179. DOI: 10.1177/1474515114521910.
  52. Clyne W., White S., McLachlan S. Developing consensus-based policy solutions for medicines adherence for Europe: a Delphi study. BMC Health Serv Res 2012;12:425. DOI: 10.1186/1472‑6963‑12‑425.
  53. Cheng K., Ingram N., Keenan J., Choudhury R. P. Evidence of poor adherence to secondary prevention after acute coronary syndromes: possible remedies through the application of new technologies. Open Heart 2015;2: e000166. DOI: 10.1136/openhrt-2014–000166.
  54. Obedinskij A. A., Kurbatov V. P., Obedinskaja N. R. et al. Effect of percutaneous transluminal coronary angioplasty in patients with chronic occlusion of right coronary artery on clinical characteristics and stress MRI indicators in postoperative period. Circulation Pathology and Cardiac Surgery 2015;19 (4):48–53. Russian (Обединский А. А., Курбатов В. П., Обединская Н. Р. и др. Влияние чрескожной транслюминальной коронарной ангиопластики при хронической окклюзии правой коронарной артерии на клинические характеристики и показатели стресс-МРТ в послеоперационном периоде. Патология кровообращения и кардиохирургия 2015;19:3:48–53.) http://dx.DOI.org /10.21688/1681‑3472‑2015‑4‑48‑53.
  55. Yasmin F., Banu B., Zakir S. M. et al. Positive influence of short message service and voice call interventions on adherence and health outcomes in case of chronic disease care: a systematic review. BMC Med Inform Decis Mak 2016;16:46. DOI: 10.1186/s12911‑016‑0286‑3
Кретов Е. И., Таркова А. Р., Анисимова В. Д., Козырь К. В., Гражданкин И. О., Байструков В. И., Зубарев Д. Д., Ибрагимов Р. У., Крестьянинов О. В., Хелимский Д. А., Найденов Р. А., Нарышкин И. А., Обединский А. А., Прохорихин А. А. Проблема приверженности к терапии в кардиологии. Кардиология. 2018;58(9):89–95.

Для доступа к данному материалу пожалуйста авторизуйтесь или зарегистрируйтесь

Зарегистрируйтесь Авторизуйтесь
Ru En